Results 151 to 160 of about 10,600 (216)

A Severe Case of Disseminated Herpes Zoster in a Patient With Crohn's Disease on Upadacitinib Who Completed the Recombinant Zoster Vaccine Series. [PDF]

ACG Case Rep J
Lue N, Burdine L, Kahan T, Reddy K, Nelson R, Lopez C, Lee M, Wolf J.   +7 more
europepmc   +1 more source

Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation Programme. [PDF]

Infect Dis Ther
Hunjan M, Curran D, Marijam A, Vekria Y, Giannelos N.   +4 more
europepmc   +1 more source

Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications. [PDF]

EClinicalMedicine
Strezova A, Díez Domingo J, Cunningham AL, Eto T, Andrews C, Arns C, Choo EJ, Hui DSC, Icardi G, McNeil SA, Põder A, Kosina P, Rombo L, Schwarz TF, Tinoco JC, Yu CJ, Wang J, Soni J, Tsang M, Leon R, Mwakingwe-Omari A, Zoster-049 Study Group.   +21 more
europepmc   +1 more source

Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017-April 2024. [PDF]

Prev Med Rep
Shu Y, Cheng W, He X, Huang L, Chen W, Zhang Q.   +5 more
europepmc   +1 more source

Effectiveness of recombinant zoster vaccine in reducing herpes zoster incidence and all-cause mortality among patients with rheumatoid arthritis: a retrospective cohort study of 21,046 individuals from TriNetX U.S. Collaborative Network. [PDF]

EClinicalMedicine
Lin YL, Wang SI, Wei JC.
europepmc   +1 more source

Post-Marketing Surveillance of Adverse Events for the Recombinant Zoster Vaccine Among the Population over 50 Years Old in Hangzhou, China. [PDF]

Vaccines (Basel)
Wang J, Du J, Liu Y, Xu Y, Han J, Zhang X.   +5 more
europepmc   +1 more source

Immunogenicity of Recombinant Zoster Vaccine: A Systematic Review, Meta-Analysis, and Meta-Regression. [PDF]

Vaccines (Basel)
Losa L, Antonazzo IC, Di Martino G, Mazzaglia G, Tafuri S, Mantovani LG, Ferrara P.   +6 more
europepmc   +1 more source

Correction: Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older. [PDF]

Pharmacoecon Open
George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, Giannelos N.   +6 more
europepmc   +1 more source

A prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the recombinant zoster vaccine in Chinese adults ≥50 years of age. [PDF]

Hum Vaccin Immunother
Pang X, Spence O, Parmar N, Wang J, Zhou T, Guo X, Colliou A, Pradeep Sarang S, Yousefi M, Yun H.   +9 more
europepmc   +1 more source

Exploring the Link between Varicella-Zoster Virus, Autoimmune Diseases, and the Role of Recombinant Zoster Vaccine. [PDF]

Biomolecules
Ishihara R, Watanabe R, Shiomi M, Katsushima M, Fukumoto K, Yamada S, Okano T, Hashimoto M.   +7 more
europepmc   +1 more source